SEC Form 4 · accession 0000882104-19-000004
PDL BIOPHARMA, INC. · PDLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Peter McLaughlin
Officer — CEO
Period of report
Dec 31, 2018
Accepted (ET)
Jan 9, 2019 · 10:26 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882104
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stockF1 | Dec 31, 2018 | D | 123,449 | $0.00 | D | 502,108 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1John McLaughlin retired from the Issuer as of December 31, 2018, and all unvested shares of restricted stock were forfeited back to the Issuer.